Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8710793 | 0.76 | HPGD (0.48) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| SCHEMBL10079150 | 0.73 | SLC6A2 (0.49) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| SCHEMBL2606076 | 0.73 | CHRNB2 (0.53) | LMNAPOLB | |
| SCHEMBL14266758 | 0.71 | LMNA (0.47) | SMN1; SMN2ALDH1A1LMNAPOLB | |
| SCHEMBL7018542 | 0.71 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| SCHEMBL9569140 | 0.69 | ALDH1A1 (0.42) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| SCHEMBL6368354 | 0.68 | ALDH1A1 (0.44) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| SCHEMBL497608 | 0.67 | — | — | |
| SCHEMBL14371832 | 0.67 | HTT (0.69) | MAPTSMN1; SMN2KDM4ETSHRHTT | |
| Methylamine SCHEMBL28610020 | 0.67 | MAPT (0.46) | MAPTSMN1; SMN2KDM4ETSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| CN-117976855-A | Preparation process of carbon-based sodium ion battery composite electrode material | 江苏传艺科技股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117976855-A | Preparation process of carbon-based sodium ion battery composite electrode material | 江苏传艺科技股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117976855-A | Preparation process of carbon-based sodium ion battery composite electrode material | 江苏传艺科技股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10174062-B2 | Activators of glucokinase | METABASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10005805-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-2185570-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | Metabasis Therapeutics, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009023718-A2 | NOVEL ACTIVATORS OF GLUCOKINASE | METABASIS THERAPEUTICS, INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1086098-B1 | THIENYL SUBSTITUTED ACYLGUANIDINES AS INHIBITORS OF BONE RESORPTION AND VITRONECTIN RECEPTOR ANTAGONISTS | AVENTIS PHARMA GMBH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-6660728-B2 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-12-09 | — | — | US | disclosed |
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | AVENTIS PHARMA DEUTSCHLAND GMBH AND GENENTECH, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6566366-B1 | For therapy of tumor growth, osteoporosis, inflammation and cardiovascular disorders | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-05-20 | — | — | US | disclosed |
| EP-0960882-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | Hoechst Marion Roussel Deutschland GmbH (DE) | 1999-12-01 | — | — | EP | disclosed |
| US-5840917-A | ADMINISTERING TO MAMMAL TO ERADICATE HELICOBACTER PYLORI | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005805-B2 | — | GCKR, GCK, HK1 | MAPT 2748/4885SMN1; SMN2 3089/4885KDM4E 4072/4885 |
| US-20030153557-A1 | Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists | ASGR1, PTMS, B3GNT2 | MAPT 4451/4885SMN1; SMN2 3592/4885KDM4E 3015/4885 |
| US-20170096440-A1 | NOVEL ACTIVATORS OF GLUCOKINASE | GCKR, GCK, HK1 | MAPT 2681/4885SMN1; SMN2 3652/4885KDM4E 3996/4885 |
| US-10174062-B2 | Activators of glucokinase | GCKR, GCK, HK1 | MAPT 2413/4885SMN1; SMN2 3576/4885KDM4E 4021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.